ReviewThrombosis journal2023
Tranexamic acid for haemostasis and beyond: does dose matter?
Review in Thrombosis journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial.Aesthetic surgery journal · 2026Trial
- Effects of tranexamic acid on postoperative knee activity and stress, and inflammation cytokines in patients undergoing total knee arthroplasty.Inflammopharmacology · 2025Trial
- Fibrin formation and lysis in hyperglycaemia - molecular and cellular drivers.Current opinion in hematology · 2026Review
- Article
- Functional Aspects of Fibrin Structure Alterations by Tranexamic Acid in the Inhibition of Fibrinolysis.Biomolecules · 2026Article
- Does Topical Tranexamic Acid Facilitate Faster Discharge Following Lung Resection? A Retrospective Cohort Analysis.Journal of clinical medicine · 2026Article
- Tranexamic acid in shoulder surgery: a comprehensive review of efficacy, safety, and clinical use.JSES reviews, reports, and techniques · 2026Review
- Local delivery of tranexamic acid for hemorrhage control in trauma: a narrative review.Frontiers in drug delivery · 2026Review
- Cell-dependent antithrombotic effect of tranexamic acid.Frontiers in immunology · 2026Article
- The Impact of Local Tranexamic Acid Infiltration on Periorbital Ecchymosis and Edema in Rhinoplasty: A Triple-Blinded Randomized Controlled Trial.Aesthetic surgery journal. Open forum · 2026Article
- Tranexamic acid does not have a dose-dependent effect on postoperative delirium after cardiac surgery - a retrospective cohort study.The journal of extra-corporeal technology · 2025Observational
- Effectiveness and Safety of Topically Applied Tranexamic Acid with Epinephrine in Surgical Procedures: A Systematic Review.European burn journal · 2025Review
- Article
- Comparative Evaluation of Local Hemostatic Agents in Minor Oral Surgical Procedures: A Randomized Clinical Trial.Cureus · 2025Article
- Halo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots.Research and practice in thrombosis and haemostasis · 2025Article
- The Influence of Tranexamic Acid (TXA) on Postoperative Infection Rates Following Total Hip Arthroplasty (THA)-A Systematic Review.Journal of clinical medicine · 2025Review
- Beyond Hemostasis: Exploring Intra-articular Tranexamic Acid's Analgesic Effect in Post-operative Care in Total Knee Arthroplasty - Original Article.Journal of orthopaedic case reports · 2025Article
- Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury.International journal of molecular sciences · 2025Review
- Article
- Tranexamic acid inhibits group A streptococci-mediated fibrinolysisFrontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the 1960's to reduce blood loss in various conditions. TXA is a lysine analogue that competes for the lysine binding sites in plasminogen and tissue-type plasminogen activator impairing its interaction with the exposed lysine residues on the fibrin surface. The presence of TXA therefore, impairs the plasminogen and tPA engagement and subsequent plasmin generation on the fibrin surface, protecting fibrin clot from proteolytic degradation. However, critical lysine binding sites for plasmin(ogen) also exist on other proteins and on various cell-surface receptors allowing plasmin to exert potent effects on other targets that are unrelated to classical fibrinolysis, notably in relation to immunity and inflammation. Indeed, TXA was reported to significantly reduce post-surgical infection rates in patients after cardiac surgery unrelated to its haemostatic effects. This has provided an impetus to consider TXA in other indications beyond inhibition of fibrinolysis. While there is extensive literature on the optimal dosage of TXA to reduce bleeding rates and transfusion needs, it remains to be determined if these dosages also apply to blocking the non-canonical effects of plasmin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.